Compare TILE & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TILE | IMCR |
|---|---|---|
| Founded | 1973 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 1994 | 2016 |
| Metric | TILE | IMCR |
|---|---|---|
| Price | $25.54 | $30.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $36.00 | ★ $61.82 |
| AVG Volume (30 Days) | ★ 624.4K | 360.0K |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.31% | N/A |
| EPS Growth | ★ 32.43 | 30.39 |
| EPS | ★ 1.96 | N/A |
| Revenue | ★ $1,386,854,000.00 | $249,428,000.00 |
| Revenue This Year | $7.00 | $14.57 |
| Revenue Next Year | $5.46 | $8.21 |
| P/E Ratio | $13.08 | ★ N/A |
| Revenue Growth | 5.41 | ★ 43.05 |
| 52 Week Low | $17.31 | $23.15 |
| 52 Week High | $35.11 | $40.71 |
| Indicator | TILE | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 36.14 | 47.81 |
| Support Level | $24.72 | N/A |
| Resistance Level | $27.13 | $34.35 |
| Average True Range (ATR) | 0.92 | 1.20 |
| MACD | 0.12 | 0.07 |
| Stochastic Oscillator | 31.22 | 67.27 |
Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment. Its products include: ESD, Acoustic, Extreme Wear, and Quick Installation System (nTx).
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.